Home > Healthcare & Medical Devices > Immunohistochemistry Market
Immunohistochemistry Market size was valued at around USD 2 billion in 2022, growing at a CAGR of 6-7% from 2023 to 2032. Immunohistochemistry (IHC) is a laboratory-based diagnostic tool, used in biological research and clinical diagnostics to identify & visualize tissue antigens. It involves conducting unique tests on the biopsy tissue sample for accurate diagnosis of various diseases.
The rising automation and machine learning implementation in immunohistochemistry (IHC), as well as the launch of various technological IHC solutions, is expected to drive the market during the forecast period. Increased product approvals and the introduction of technologically-improved IHC systems for disease diagnosis are fueling market expansion. For instance, in March 2021, Roche launched the DISCOVERY Green HRP kit to identify & analyze biomarkers and cell types in tissue-based research. This kit can be used with other detection kits to boost the multiplexing capability of in-situ hybridization and IHC. The immunohistochemistry (IHC) technique is confined to single parametric analyses of a sample.
By product, immunohistochemistry market from the antibody segment to account for the highest share in 2023. Antibodies are used in several applications including pathology, neuropathology, and hematopathology, and play a critical role in disease diagnosis and drug testing. The increasing product launches by major companies in the market are set to fuel segment outlook.
Based on application, the diagnosis segment is likely to dominate the market owing to the increasing prevalence of various diseases such as cancer. This, in turn, will augment the demand for disease diagnosis equipment. According to the American Cancer Society, Inc., around 1.9 million new cancer cases are poised to be diagnosed in the U.S. in 2023.
The Asia Pacific immunohistochemistry market is anticipated to witness booming growth due to increased medical tourism, the implementation of new ICT standards in Japan, China’s rising focus on R&D, investments, and reforms to upgrade its healthcare infrastructure, and rapid expansion in the healthcare business in India.
The prominent players in the immunohistochemistry market are Thermo Fisher Scientific Inc., Merck KGaA, F. Hoffmann-La Roche Ltd., Danaher Corporation, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Bio SB, Agilent Technologies, Inc., and Abcam plc.